Margin Erosion And Geopolitical Risks Will Hinder Clinical Trials

Published
16 Apr 25
Updated
30 Jul 25
AnalystLowTarget's Fair Value
US$163.85
9.0% overvalued intrinsic discount
30 Jul
US$178.56
Loading
1Y
-45.0%
7D
11.8%

Author's Valuation

US$163.8

9.0% overvalued intrinsic discount

AnalystLowTarget Fair Value

Shared on07 May 25
Fair value Decreased 7.57%

AnalystLowTarget has decreased revenue growth from 1.1% to -0.5% and decreased future PE multiple from 20.6x to 17.8x.

Shared on30 Apr 25
Fair value Increased 1.37%

AnalystLowTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Increased 21%

AnalystLowTarget made no meaningful changes to valuation assumptions.